+

WO2007016350A3 - Modified release tablet formulations with enhanced mechanical properties - Google Patents

Modified release tablet formulations with enhanced mechanical properties Download PDF

Info

Publication number
WO2007016350A3
WO2007016350A3 PCT/US2006/029427 US2006029427W WO2007016350A3 WO 2007016350 A3 WO2007016350 A3 WO 2007016350A3 US 2006029427 W US2006029427 W US 2006029427W WO 2007016350 A3 WO2007016350 A3 WO 2007016350A3
Authority
WO
WIPO (PCT)
Prior art keywords
mechanical properties
modified release
release tablet
tablet formulations
enhanced mechanical
Prior art date
Application number
PCT/US2006/029427
Other languages
French (fr)
Other versions
WO2007016350A2 (en
Inventor
Amir H Shojaei
Melissa E Culp
Original Assignee
Supernus Pharmaceuticals Inc
Amir H Shojaei
Melissa E Culp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc, Amir H Shojaei, Melissa E Culp filed Critical Supernus Pharmaceuticals Inc
Priority to CA002616845A priority Critical patent/CA2616845A1/en
Priority to EP06788799A priority patent/EP1909767A2/en
Priority to JP2008524198A priority patent/JP2009502957A/en
Publication of WO2007016350A2 publication Critical patent/WO2007016350A2/en
Publication of WO2007016350A3 publication Critical patent/WO2007016350A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of formulating a drug in solid dosage form of a specified hardness, the drug containing at least one pharmaceutically active agent that has a pH dependent release profile, at least one non-pH dependent sustained release agent, and an effective amount of Eudragit L100-55.
PCT/US2006/029427 2005-07-28 2006-07-28 Modified release tablet formulations with enhanced mechanical properties WO2007016350A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002616845A CA2616845A1 (en) 2005-07-28 2006-07-28 Modified release tablet formulations with enhanced mechanical properties
EP06788799A EP1909767A2 (en) 2005-07-28 2006-07-28 Modified release tablet formulations with enhanced mechanical properties
JP2008524198A JP2009502957A (en) 2005-07-28 2006-07-28 Sustained release tablet formulation with improved mechanical properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70300005P 2005-07-28 2005-07-28
US60/703,000 2005-07-28

Publications (2)

Publication Number Publication Date
WO2007016350A2 WO2007016350A2 (en) 2007-02-08
WO2007016350A3 true WO2007016350A3 (en) 2007-05-31

Family

ID=37692541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029427 WO2007016350A2 (en) 2005-07-28 2006-07-28 Modified release tablet formulations with enhanced mechanical properties

Country Status (4)

Country Link
EP (1) EP1909767A2 (en)
JP (1) JP2009502957A (en)
CA (1) CA2616845A1 (en)
WO (1) WO2007016350A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087663A2 (en) * 2007-11-30 2009-07-16 Sun Pharmaceutical Industries Ltd. Oral controlled release coated tablet
JP5719776B2 (en) 2008-11-13 2015-05-20 ノグラ ファーマ リミテッド Antisense compositions and their production and use
AT10562U3 (en) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag A NEW COMPOSITION FOR TREATING AN ESSENCIAL THROMBOCYTEMIA
ES2733133T3 (en) * 2010-02-03 2019-11-27 Pharma Two B Ltd Rasagiline extended-release formulations and their uses
CN102138906B (en) * 2011-04-11 2012-09-05 合肥合源药业有限公司 Clonidine hydrochloride sustained release micropill preparation
TW202400130A (en) 2022-06-15 2024-01-01 日商澤井製藥股份有限公司 Guanfacine hydrochloride containing pharmaceutical preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168404A1 (en) * 1998-07-20 2002-11-14 Isabelle Rault Use of an acrylic type polymer as disintegrating agent
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168404A1 (en) * 1998-07-20 2002-11-14 Isabelle Rault Use of an acrylic type polymer as disintegrating agent
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OFOEFULE S I ET AL: "USE OF ACRYCLIC AND METACRYLIC ACID DERIVATIVES AS SUSTAINED RELEASE MATRICES FOR THEOPHYLLINE HYDRATE TABLETS", BOLLETTINO CHIMICO FARMACEUTICO, SOCIETA EDITORIALE FARMACEUTICA, MILANO, IT, vol. 138, no. 10, 1999, pages 526 - 530, XP001030890, ISSN: 0006-6648 *
SCHULZE M D ET AL: "Indices of tableting performance for acrylic resin polymers with plastic and brittle drugs", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 1993 UNITED STATES, vol. 19, no. 12, 1993, pages 1393 - 1411, XP008077210, ISSN: 0363-9045 *
TAKKA S ET AL: "INFLUENCE OF METHACRYLIC ACID AND HYDROXYPROPYLMETHYL CELLULOSE ON THE TABLET PROPERTIES AND IN VITRO RELEASE OF DEXTROMETHORPHAN HYDROBROMIDE", PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 58, no. 12, December 2003 (2003-12-01), pages 886 - 890, XP001178399, ISSN: 0031-7144 *

Also Published As

Publication number Publication date
JP2009502957A (en) 2009-01-29
EP1909767A2 (en) 2008-04-16
WO2007016350A2 (en) 2007-02-08
CA2616845A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2011049706A8 (en) Orally transformable tablets
WO2010035273A3 (en) Novel gastroretentive delivery system
TR200200562T2 (en) Pharmaceutical compositions for oral release that can be secreted in the body in a controlled manner and prevent unpleasant taste
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2007036952A3 (en) Novel sustained release dosage form
WO2007135193A3 (en) Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
WO2006084164A3 (en) Gastric retention and controlled release delivery system
IL188744A0 (en) High drug load formulations and dosage forms
WO2007050294A3 (en) Liquid dosage forms having enteric properties of delayed and then sustained release
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
WO2006138048A3 (en) Formulations comprising fluphenazine or derivatives thereof
ATE505203T1 (en) PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN
BG108516A (en) Pharmaceutical formulation
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
EP1783137A4 (en) Galactose derivative, drug carrier and medicinal composition
WO2005007137A3 (en) Tablets containing ambroxol
WO2010052466A8 (en) Pharmaceutical aerosol composition
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2008039351A3 (en) Method of manufacturing tablets containing pharmacologically active agents
WO2007075980A3 (en) Lansoprazole orally disintegrating tablets
WO2011058336A3 (en) Tablet comprising gum arabic

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2616845

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008524198

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006788799

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载